Activator of apoptosis harakiri (HRK)

Activator of apoptosis harakiri (HRK) is a pro-apoptotic BH3-only protein within the BCL-2 family, localized to intracellular membranes, notably the mitochondrial outer membrane. It promotes apoptosis by binding to and antagonizing anti-apoptotic proteins BCL-2 and BCL-xL through its BH3 domain, thereby activating the intrinsic mitochondrial apoptotic pathway and leading to caspase activation and cell death. HRK is transcriptionally induced particularly under conditions of trophic factor deprivation and is directly upregulated by transcription factors such as E2F1, linking disruptions in cell cycle regulation to apoptosis. HRK plays roles in neuronal death and has implications in neurodegeneration, as well as in tumorigenesis; its expression and activity are tightly regulated and can sensitize cancer cells (e.g., glioblastoma) to pro-apoptotic treatments such as TRAIL, especially when in combination with agents like histone deacetylase inhibitors. HRK silencing, often via methylation, has been implicated in several tumor contexts and is associated with increased cell survival, making it a promising target for combination pro-apoptotic therapies.

Other names

HarakiriBID3DP5Neuronal death protein DP5Death protein 5BH3-interacting domain-containing protein 3HARAKIRIActivator of apoptosis HRKdeath protein 5harakiriBCL2 interacting protein (contains only BH3 domain)

Sensitization to apoptosis via intrinsic and extrinsic pathways (when upregulated/interacted with by drugs); Antagonism of anti-apoptotic BCL-2/BCL-xL, thus promoting caspase activation and PARP cleavage